JNJ slips nearly 6% despite Q3 earnings beat
FROM THE WIRE · FINANCE.YAHOO.COM
Shares of Johnson & Johnson JNJ initially dropped nearly 6% on Oct. 13, after announcing third-quarter 2026 results. Although JNJ beat Wall Street estimates on both the top and bottom lines, the stock initially declined primarily because its MedTech segment fell short of…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralA mega-cap healthcare stock's reaction shows how the MedTech segment can weigh on sector sentiment.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01JNJ beat Wall Street estimates on both revenue and earnings in Q3 2026.
- 02The initial drop was driven mainly by the MedTech segment falling short of expectations.
- 03The stock has risen 2.1% since the announcement and is up 22.4% year to date.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets